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Background. Patients with diabetes mellitus are more prone to bacterial sepsis, but there are conﬂicting data on
whether outcomes are worse in diabetics after presentation with sepsis. Glyburide is an oral hypoglycemic agent
used to treat diabetes mellitus. This KATP-channel blocker and broad-spectrum ATP-binding cassette (ABC)
transporter inhibitor has broad-ranging effects on the immune system, including inhibition of inﬂammasome
assembly and would be predicted to inﬂuence the host response to infection.
Methods. We studied a cohort of 1160 patients with gram-negative sepsis caused by a single pathogen
(Burkholderia pseudomallei), 410 (35%) of whom were known to have diabetes. We subsequently studied
prospectively diabetics with B. pseudomallei infection (n 5 20) to compare the gene expression proﬁle of peripheral
whole blood leukocytes in patients who were taking glyburide against those not taking any sulfonylurea.
Results. Survival was greater in diabetics than in nondiabetics (38% vs 45%, respectively, P 5 .04), but the
survival beneﬁt was conﬁned to the patient group taking glyburide (adjusted odds ratio .47, 95% conﬁdence interval
.28–.74, P 5 .005). We identiﬁed differential expression of 63 immune-related genes (P 5 .001) in patients taking
glyburide, the sum effect of which we predict to be antiinﬂammatory in the glyburide group.
Conclusions. We present observational evidence for a glyburide-associated beneﬁt during human melioidosis
and correlate this with an anti-inﬂammatory effect of glyburide on the immune system.
A recurring theme in the sepsis literature is that the in-
ﬂammatory response is essential, yet high levels of in-
ﬂammation correlate with mortality in observational
studies of human sepsis [1]. This has led to the notion
that containment of an excessive immune response
might improve outcome. Glyburide USAN (glibencla-
mide rINN) is a KATP-channel blocker and broad-
spectrum ATP-binding cassette (ABC) transporter in-
hibitor used to treat type 2 diabetes. The relevant
pharmacological drug action in diabetes is inhibition of
KATP channels in pancreatic b cells leading to stimula-
tion of insulin secretion, but there is evidence from
experimentalmodelsthatglyburidealsohasawiderange
of antiinﬂammatory effects. The best described of these
is an inhibitory effect on the host inﬂammasome, an
intracellular protein complex present in macrophages
that activates caspase 1 and produces active interleukin
(IL)-1b and IL-18 when presented with an appropriate
inﬂammatory stimulus [2]. The inﬂammatory effect of
glyburide on outcome from sepsis has not been well
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commonly take glyburide and are at greater risk than the healthy
population of developing bacterial infection.
We report here the effect of glyburide on outcome in a cohort
of over 1000 patients infected with a single pathogen (melioi-
dosis, which is Burkholderia pseudomallei infection). Melioidosis
is an important clinical model because diabetes is present in
up to 50% of patients, manifestations of infection are often
severe, mortality is around 40% in northeast Thailand where
most cases are diagnosed, and glyburide therapy is prescribed in
around half of diabetics in this region. We found that patients
with a preadmission diagnosis of diabetes were protected from
death but that this survival advantage was conﬁned to those
patients taking glyburide prior to the onset of infection. We
hypothesized that glyburide was modulating the immune re-
sponse to B. pseudomallei infection, a hypothesis supported
by the ﬁndings of a study of the gene-expression proﬁles of
peripheral blood leukocytes in which we compared diabetic
patients with melioidosis or otherwise healthy diabetic patients
who were or were not taking glyburide.
PATIENTS AND METHODS
Cohort Study
We prospectively identiﬁed all patients aged 15 years or older
presenting to Sappasithiprasong Hospital, Ubon Ratchathani,
northeastThailand,withculture-conﬁrmedmelioidosisbetween
1 January 2002 and 31 December 2006. Patients on their ﬁrst
admission for culture-conﬁrmed melioidosis were eligible, but
patients younger than 15 years of age were excluded because
pediatric cases have a different clinical presentation and prog-
nosis. There were no other exclusion criteria.
Patients were classiﬁed into 3 groups according to diabetes
status at presentation: known diabetes, hyperglycemia, or no
diabetes. Patients with a preexisting diagnosis of diabetes mel-
litus were classiﬁed as having known diabetes. The hyperglyce-
mia group comprised patients not previously known to have
diabetes, who had either a blood glucose .200 mg/dL (11.1
mmol/L) at any point during the admission or new diabetes
diagnosed after recovery as deﬁned by World Health Organi-
zation(WHO) criteria. Wedidnotsubclassifythisgroupfurther
for the following reasons: Melioidosis is a common ﬁrst pre-
sentation of type 2 diabetes in this region [3], and an associated
mortality of 50% (half of which occurs in the ﬁrst 48 h) means
that a new diagnosis of diabetes cannot be made for a signiﬁcant
proportion of patients, and hyperglycemic patients who die are
morelikely to be classed as havingsepsis-induced hyperglycemia
whereas patients who survive are more likely to be classed as
havinga new diagnosis ofdiabetes.Patientswho didnot fall into
the known diabetes or hyperglycemia groups were classiﬁed as
having no diabetes. Hemoglobin A1c (HbA1c)v a l u e sw e r en o t
available for patients in this cohort. Further deﬁnitions aregiven
in the Supplementary Methods.
Statistical Analysis
Analyses were performed using Stata/SE version 9 software
(StataCorp). Differences between the 3 patient groups were
compared using Fisher exact test for categorical variables and
Mann-WhitneyUtestforcontinuousvariables.Timetodeathto
28 days was analyzed using the Kaplan-Meier method; patients
discharged alive from hospital within 28 days were assumed to
have survived, but patients who self-discharged against medical
advice were censored on theday of discharge. Logistic regression
models were used to adjust for confounders identiﬁed using
a conceptual framework [4]. Further details are given in the
Supplementary Methods.
Gene Expression Study
We compared peripheral white blood cell gene expression in (1)
diabetics who were taking glyburide (case) or were not taking
this oranothersulfonylurea (control)at the timeofadmission to
Sappasithiprasong Hospital with culture-conﬁrmed melioidosis
and sepsis and (2) otherwise healthy diabetics attending a rou-
tine outpatient clinic who were taking glyburide (case) or were
not taking this or another sulfonylurea (control). Eligible cases
for both studies were persons aged between 18 and 75 years. A
total of 40 patients (10 in each group) were recruited in the
period31January2008to31October2008.Diabeteswasdeﬁned
as an abnormal HbA1c at enrollment (7.8% or greater [5], Bio-
Rad D-10 fully automated HbA1c system, Bio-Rad Laboratories)
or a previous diagnosis of diabetes. The HbA1c concentration
allowed us to identify patients with previously unrecognized
diabetes who would otherwise die before we could make a di-
agnosis of diabetes by WHO criteria.
Blood was collected in PaxGene Blood RNA tubes (Pre-
AnalytiX). Gene expression was assayed using the Illumina
HumanWG-6 v3.0 Expression BeadChip (Illumina), and results
wereconﬁrmedbyquantitativereverse-transcriptase polymerase
chain reaction (RT-PCR) (see Supplementary Methods).
Gene ontology overrepresentation analysis was performed
using InnateDB (www.innatedb.ca) and the P values reported
are for the hypergeometric test. Gene lists were supplemented by
manual literature searches for genes not curated by InnateDB.
Microarray data have been deposited at ArrayExpress, EMBL -
EBI (accession number E-TABM–852-n).
Ethics
Approval was obtained from the Ethical and Scientiﬁc Review
subcommittee of the Thai Ministry of Public Health to use in-
formation collected during the cohort study. We obtained ap-
proval from the Oxford Tropical Research Ethics Committee
and the Ethics Committee of the Faculty of Tropical Medicine,
Mahidol University, for the gene expression study. Written
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speaker. All procedures performed were in accordance with the
Helsinki Declaration of 1975 (revised 1983).
RESULTS
Diabetes and Mortality
We identiﬁed 1384 patients with culture-positive melioidosis, of
whom 224 were removed from the ﬁnal analysis for reasons
shown in Figure 1. Of the remaining 1160 patients, 410 (35%)
had known diabetes, 250 (22%) had hyperglycemia, and 500
(43%) had no diabetes. Patient characteristics, clinical features
of melioidosis, and primary and secondary outcomes were
compared between the 3 groups, using the no diabetes group as
the comparator for the 2 other groups (Table 1). In-hospital
mortality was lower in patients with known diabetes compared
with nondiabetics (P 5 .04), with no difference observed be-
tween nondiabetics and patients with hyperglycemia. These
ﬁndings were reproduced in the survival analysis (Figure 2A).
A previous study conducted at the same hospital but in a dif-
ferent (earlier) patient cohort reported an inverse association
between diabetes and mortality (unadjusted odds ratio [OR]
.49) [6]. We conﬁrmed this observation in our independent
cohort (OR .76; adjusted odds ratio [AOR] .78, 95% conﬁdence
interval [CI] .59–1.0, P 5 .07), and extended previous ob-
servations that patients in the hyperglycemia group had no
survival advantage (OR 1.1; AOR 1.1, 95% CI 0.8–1.5, P 5 .52)
(Table 2, Model A). Thirty-four patients self-discharged against
medical advice; results of the logistic regression analyses were
not different if these patients were assumed to have lived or died
(data not shown).
Glyburide and Mortality
We hypothesized that the association between diabetes and
a reduced risk of death was due to the treatment received for
diabetes and/or melioidosis. This was tested in a second logistic
regression model (Table 2, Model B). We considered drugs
prescribed for diabetes (glyburide, metformin, insulin) prior to
admission, noting that more than half of known diabetics were
receivingglyburide(Table1).Weincludedthe administration of
appropriate admission antimicrobial therapy because the asso-
ciation between diabetes and melioidosis is well described and
could lead clinicians to prescribe these at an earlier stage in
diabetic patients. The AOR for death was lower for patients who
received glyburide therapyprior to admission(AOR.47, 95% CI
.28–.74, P 5 .005) and for those receivingeffective antimicrobial
chemotherapy at admission (AOR .23, 95% CI .17–.34, P ,
.001) (Table 2, Model B). Neither metformin nor insulin
treatment was associated with survival in any analysis. The un-
adjusted survival curve for patients in the glyburide group is
shown in Figure 2B. Patients in the known diabetes group were
more likely to receive effective antimicrobial therapy on ad-
mission compared with patients without diabetes (88% vs 73%,
respectively, P , .001), an association that was seen in each of
the treatment groups (glyburide 92%, P , .001; metformin
98%, P , .001; insulin 90%, P 5 .02), but the association be-
tween glyburide therapy and survival was independent of ad-
mission antimicrobial therapy (Table 2).
We used logistic regression to evaluate the relationship be-
tween diabetes and the secondary outcome measures. We found
that diabetes was negatively associated with both hypotension
and respiratory failure (AOR .84 [Model C] and AOR .73
[Model E], respectively, see Supplementary Table 1), but that
this association did not persist after adjustment for treatment
(antimicrobials and antidiabetic treatment) (Models D and F,
Supplementary Table 1). However, glyburide was negatively
associated with both hypotension (AOR .48, 95% CI .30–.78,
P 5 .007)and respiratory failure (AOR .50, 95% CI.28–.86,P 5
.01), as was effective antimicrobial therapy within 24 hours
of admission (AOR .51, 95% CI .37–.70, P , .001 and AOR .42,
95% CI .31–.58, P , .001, respectively) (Models D and F,
Supplementary Table 1). In a sensitivity analysis, if patients
taking an unknown oral drug were placed in the glyburide
group, then the association between glyburide and hypotension
(AOR .65, 95% CI .39–1.1, P 5 .09) and between glyburide
and respiratory failure (AOR .60, 95% CI .36–1.0, P 5 .05)
was no longer signiﬁcant statistically.
Glyburide and Inflammation
Having observed an association between glyburide and survival,
we initially postulated that glyburide was acting as an antimi-
crobial drug based on its structural homology with the sulfo-
namides (to which B. pseudomallei is susceptible). However,
a solution of glyburide in dimethyl sulfoxide did not inhibit the
growth of B. pseudomallei when applied to a lawn of bacteria on
solidagar(datanotshown).Glyburide isabroad-spectrumABC
transporter inhibitor that alters responses of macrophages to
a range of stimuli in vitro and in vivo. We therefore used pe-
ripheral leukocyte gene expression as a screening tool to identify Figure 1. Summary of patient recruitment for cohort study.
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No Diabetes
(n 5 500)
Known Diabetes
(n 5 410)
Hyperglycemia
(n 5 250) Total
(n 5 1160)
No. (%) No. (%) P value
a No. (%) P value
a Row total (%)
Female 165 (33) 219 (53) – 114 (46) – 498 (43)
Male 335 (67) 191 (47) ,.001 136 (54) .001 662 (57)
Median age (y, IQR) 52 (39–63) 51 (42–59) .40
b 51 (42–59) .22
b –
Rice farmer 367 (73) 326 (80) .04 212 (85) ,.001 905 (79)
Median (IQR) days of infective
symptoms prior to presentation
7 (4–15) 10 (5–21) .02
b 8 (5–15) .03
b 7 (5–20)
Diabetes treatment
c
Glyburide – 208 (51) – 208 (18)
Metformin – 51 (12) – 50 (4)
Insulin – 81 (20) – 81 (7)
Other sulphonylurea – 10 (2) – 10 (.9)
Unknown oral drug – 51 (12) – 51 (4)
No medication – 53 (13) – 53 (5)
Risk factors for melioidosis
Chronic kidney disease 54 (11) 36 (9) .32 9 (4) .001 99 (9)
Nephrolithiasis 35 (7) 15 (4) .03 6 (2) .01 56 (5)
Corticosteroid use 21 (4) 19 (5) .75 9 (4) .84 49 (4)
Thalassaemia 11 (2) 4 (1) .19 2 (.8) .24 17 (1)
Malignancy 9 (2) 1 (.2) .03 1 (.4) .18 11 (1)
Chronic liver disease 6 (1) 5 (1) 1.00 1 (.4) .43 12 (1)
Organ involvement
Pneumonia 190 (38) 154 (38) .95 117 (47) .02 461 (40)
Skin or soft tissue 86 (17) 94 (23) .04 42 (17) .92 222 (19)
Urinary tract 78 (16) 48 (12) .10 15 (6.0) ,.001 141 (12)
Liver abscess(es) 33 (7) 48 (12) .01 27 (11) .06 108 (9)
Spleen abscess(es) 45 (9) 45 (11) .37 35 (14) .04 125 (11)
Septic arthritis 24 (5) 40 (10) .004 24 (10) .02 88 (8)
Distribution of disease
Bacteremia 274 (55) 238 (58) .35 164 (66) .005 676 (58)
Single organ disease 291 (58) 240 (59) .95 146 (58) 1.00 677 (58)
Multiorgan disease 110 (22) 102 (25) .31 58 (23) .71 270 (23)
Complications
Hypotension 187 (37) 135 (33) .16 99 (39) .58 421 (36)
Respiratory failure 179 (36) 117 (29) .02 101 (40) .23 397 (34)
Sepsis
d 392 (78) 334 (81) .28 209 (84) .10 935 (81)
Antibiotic treatment and
in-hospital mortality
Effective antibiotic treatment
within 24 h of admission
367 (73) 359 (88) ,.001 212 (85) ,.001 938 (81)
Died 225 (45) 157 (38) .04
f 117 (47) .64
f 499 (43)
Discharged well 254 (51) 245 (60) – 128 (51) – 627 (54)
Outcome unknown
(self-discharged)
21 (4) 8 (2) – 5 (2) – 34 (3)
NOTE. IQR 5 interquartile range. Anatomical sites for which there were fewer than 20 cases in the 5-year period are omitted from the table. Variables recording
organ involvement at 10 sites are not shown here, because there were fewer than 20 events recorded: parotitis, pleural disease, central nervous system disease,
peritonitis, pericarditis, osteomyelitis, prostatitis, thyroiditis, ophthalmitis, and cholecystitis. They were, however, taken into account when counting the number of
organs involved.
a Fisher exact test, except where indicated.
b Mann-Whitney U test with No diabetes as the comparator group, because the data were non-normal and could not be transformed to normal.
c Numbers do not add up to 410 (100%) because some patients were taking more than 1 type of medication.
d Sepsis deﬁned as temperature .38Co r,36C, heart rate .90 beats per minute, respiratory rate .20 breaths per minute, or total leucocyte count .12 3 10
9
cells/L.
f Patients who took their own discharge were counted as alive.
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action of glyburide. We compared gene expression proﬁles in 10
diabetic patients who were taking glyburide at the time of pre-
sentation with melioidosis against 10 diabetic melioidosis pa-
tients who were not taking this or another sulfonylurea. There
were no signiﬁcant differences in any of the clinical parameters
recorded for the 2 patient groups (Supplementary Table 2). The
expression of 205 probes (representing 186 distinct genes) were
signiﬁcantly different in patients taking glyburide compared to
those who were not (Figure 3). Sixty-three immune-related
genes were differentially expressed in melioidosis patients on
glyburide (P5.001),the neteffectofwhichwouldbepostulated
to be anti-inﬂammatory (Supplementary Table 3). Prominent
among the immune-related genes include those implicated in
neutrophil activation, endothelial adhesion, and transmigration.
There was no statistical difference in neutrophil, lymphocyte, or
monocytes counts between the 2 groups (Supplementary Table
2), indicating that this was not merely an effect of differences in
cellular blood constituents. In the microarray analysis, tumor
necrosis factor (TNF)-a, IL-18R1, and IL-8 expression were all
downregulated; interferon (IFN)-c showed a modest trend to
downregulation.QuantitativeRT-PCRcorroboratedtheTNF-a
and IL-18R1 results; IFN-c was down-regulated by this meth-
odology, but the IL-8 results were not conﬁrmed (Supplemen-
tary Table 5).
We sought further evidence for an effect of glyburide on gene
expression proﬁles in otherwise healthy diabetics who were
taking glyburide (n 5 10) or who were not taking a sulfonylurea
drug (n 5 10). There were no signiﬁcant differences in baseline
parameters between the 2 groups (Supplementary Table 2). We
found that 31 probes (29 distinct genes) were signiﬁcantly dif-
ferent in patients taking glyburide compared to those who were
not, 13 of which were immune related (Supplementary Table 4),
again suggesting an anti-inﬂammatory effect. Of note, genes
associated with neutrophil function were down-regulated in the
glyburide group (P , .001); however, we found no direct an-
tiinﬂammatory effect of glyburide on neutrophils in vitro
(Supplementary Results).
DISCUSSION
This study of severe gram-negative sepsis has demonstrated
a clear association between glyburide and a survival beneﬁt. This
second-generation sulfonylurea is widely used to treat type 2
diabetes and acts by inhibiting ATP-sensitive potassium chan-
nels (KATP channels) in pancreatic b cells, leading to stimulation
of insulin secretion. KATP channels are also expressed in the
heart and on vascular smooth muscle, and excessive opening of
vascular KATP channels in sepsis (due to a fall in the ATP/ADP
ratio, pH or oxygen tension, or a rise in intracellular lactate)
leads to hyperpolarization of the cell membrane, a blocking of
the calcium inﬂux, and loss of vascular tone (contributing to the
‘‘vascular paresis’’ of septic shock). By blocking vascular smooth
muscle KATP channels, glyburide is able to protect from shock in
animal models of sepsis, although this did not translate into
a detectable effect on cardiovascular parameters in 2 small
clinical trials in which glyburide was given at doses normally
Figure 2. Kaplan-Meier survival curves of 1160 patients with
melioidosis. The survival curves in panel A show that patients with
diabetes have a survival advantage after the development of melioidosis,
but the survival curves in panel B indicate that this effect was seen only in
the patient group taking glyburide. The P values reported are for the log-
rank test. Median duration of follow-up was 6.5 days and total follow-up
was 11,845 patient days.
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termine an effect on mortality and neither looked at other end
points such as respiratory failure.
A retrospective study of 12.5 million sepsis patients, in which
patients with diabetes had a lower mortality rate than those
without diabetes (18.5% vs 20.6%, respectively, P , .05) as-
cribed this in part to a lower incidence of acute respiratory
failure in diabetics compared to nondiabetics (9% vs 14%, re-
spectively, P , .05) [9]. A second study conducted by the same
investigators of 113 intensive care unit patients showed that
a preadmission diagnosis of diabetes (but not hyperglycemia)
protected patients from acute respiratory distress syndrome
(ARDS) [10]. Neither study looked for an effect of diabetes
treatment.
Glyburide is known to have a wide range of anti-inﬂammatory
effects, one of which is an inhibitory effect on inﬂammasome
assembly [2]. The inﬂammasome is an intracellular protein
complex present in macrophages that activates caspase 1 and
converts pre-formed IL-1b and IL-18 to their active forms
when presented with an appropriate inﬂammatory stimulus
[11]. IL-1b and IL-18 levels are high in bronchoalveolar lavage
ﬂuid from patients with acute lung injury/acute respiratory
distress syndrome (ALI/ARDS) and correlate with mortality
[12, 13], which leads us to hypothesize that inhibition of in-
ﬂammasome assembly may be a mechanism for our ﬁnding
that glyburide therapy and respiratory failure are inversely as-
sociated. It is also unsurprising that fewer genes were found to
be differentially expressed in the otherwise healthy diabetic
controls than in the patients with melioidosis, as the in-
ﬂammasome is only assembled as part of the acute in-
ﬂammatory response and so we expect to see little effect of
glyburide when there is no active inﬂammation.
Neutrophil recruitment to an area of tissue inﬂammation or
infection can also be linked to the inﬂammasome through the
action of IL-1b. While IL-1b is not itself a chemoattractant for
neutrophils[14],IL-1b upregulatestheexpressionofendothelial
intercellular adhesion molecules essential for the recruit of
neutrophils to an area of inﬂammation [15, 16, 17]. Neutrophils
are a critical component of the host response to B. pseudomallei
in vivo [18], but may also drive tissue injury and organ damage
Table 2. Effect of Diabetes on Mortality
Parameter
Univariate Analysis
Logistic Regression
Model A (n 5 1160)
Logistic Regression
Model B (n 5 1109)
c
OR (95% CI) AOR (95% CI) AOR (95% CI)
No diabetes
a 1.0 — 1.0 — 1.0 —
Known diabetes .76 (.58–.99) .78 (.59–1.0) 1.4 (.89–2.3)
Hyperglycaemia 1.1 (.79–1.5) 1.1 (.81–1.5) 1.4 (.98–1.9)
Age
b 1.1 (1.0–1.2) 1.1 (1.0–1.2) 1.1 (.99–1.2)
Male sex 1.2 (.94–1.5) 1.1 (.89–1.5) 1.0 (.78–1.3)
Rice farming .97 (.74–1.3) 1.0 (.75–1.3) 1.2 (.86–1.6)
Corticosteroid use 1.5 (.86–2.7) 1.6 (.87–2.8) 1.0 (.62–2.2)
Chronic kidney disease 2.8 (1.8–4.3) 2.2 (1.6–4.0)
Glyburide treatment
c .48 (.35–.67) .47 (.28–.74)
Metformin treatment
c .61 (.33–1.1) 1.1 (.62–2.4)
Insulin treatment
c .79 (.49–1.3) .65 (.37–1.2)
Effective admission
antibiotic treatment
c
.22 (.16–.31) .23 (.17–.34)
NOTE. AOR 5 adjusted odds ratio; CI 5 conﬁdence interval; OR 5 odds ratio (not adjusted). An odds ratio ,1 indicates association with survival, whereas an
odds ratio .1 indicates association with mortality. The ﬁrst column describes the contribution of each factor in isolation. The second column (model A) attempts to
explain the effect of diabetes by adjusting for several possible confounders for diabetes simultaneously; the third column (model B) adjusts additionally for the effect
of diabetes treatment and postadmission antibiotics. Exposures of interest are highlighted in bold.
When considered in isolation, diabetes (OR .76), glyburide treatment (OR .48), and effective admission antibiotic treatment (OR .22) were associated with survival.
The effect of diabetes persisted after correcting for confounders for diabetes (AOR .78, model A). When the effect of glyburide treatment and effective admission
antibiotic were taken into account, diabetes was no longer associated with survival (AOR 1.4, model B). Sensitivity analysis. We conducted a sensitivity analysis to
examine the impact of the missing data. Model A was constructed by assigning the patients who self-discharged as ‘‘alive’’; but if these patients were instead
assigned as ‘‘dead’’, then the AOR for known diabetes in model A became .71 (.54–.93, P 5 .01). In model B, assigning the patients who self-discharged to ‘‘dead’’
caused the AOR for known diabetes to become 1.3 (.79–2.1, P 5 .31), glyburide treatment AOR .48 (.28–.83, P 5 .008), and effective admission antibiotic treatment
AOR .18 (.13–.27, P , .001). Putting the patients on an unknown oral diabetes medication into the glyburide group (n 5 1160) in model B meant the AOR for
glyburide treatment rose to .59 (.36–.97, P 5 .04) and effective admission antibiotic treatment became .24 (.17–.34, P , .001). When the patients on an unknown
oral diabetes medication were put into the metformin group (n 5 1160), the AOR for glyburide treatment became .49 (.30–.78, P 5 .003) and effective admission
antibiotic treatment became .25 (.18–.34, P , .001).
a Comparator group.
b Number of decades above age 15 years.
c The patients on unknown oral diabetes medication were omitted (n 5 1109) in model B and in the unadjusted OR for treatment variables.
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neutrophil-rich and some animal models of ARDS are neutro-
phil-dependent [20]. Glyburide has been shown to prevent
neutrophil extravasation and accumulation in animal models
[19], andthismayrepresentindirect evidencethatglyburidewas
responsible for reducing the incidence of respiratory failure in
study patients taking this drug. We speculate that conﬂicting
evidence from previous observational studies of the impact of
diabetes on outcomes from bacterial sepsis may be explained in
part by differences in the management of type 2 diabetes be-
tween Europe (metformin has been available in Britain since
1958 and has traditionally been used ﬁrst-line) and the United
States (where sulfonylureas have often been used ﬁrst-line [21]
and metformin has only been available since 1995).
Glyburide has been said to inhibit the inﬂammasome by
blocking KATP channels[22]but thisseemsunlikely [23]and the
Figure 3. Differential expression of inflammation-associated genes in diabetic patients with acute melioidosis with or without glyburide (Gb). Genes
that are up-regulated are shown in red, down-regulated in green; genes in black are not differentially expressed. The gene symbols used are those
assigned by the HUGO gene nomenclature committee.
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receptor is one possibility [25, 26]. The development of in-
ﬂammasome inhibitors that do not have the hypoglycemic
effectsofglyburidemaydependonunravelingthispathway.Our
enthusiasm for this approach is tempered by the ﬁnding of
one multicenter trial that direct IL-1 blockade does not improve
survival in all-cause sepsis [27]. Our study is also unable to
provide guidance on whether any beneﬁt would be seen were
glyburide started following the onset of infection in nondiabetic
patients.
Inﬂammasome function is not restricted to IL-1b activation
and inﬂammasome inhibition is not the only action of gly-
buride. Glyburide is a broad-spectrum inhibitor of ABC trans-
porters [28–30], and many members of this family have been
implicated in regulating immune function. Glyburide also has
a direct effect on neutrophil chemotaxis when administered at
a dose 100 times the concentration achievable in humans [31],
although we found no direct effect of glyburide on neutrophils
in vitro (Supplementary Results).
In seeking confounders for our study, we considered
whether glyburide treatment was simply a marker for less
advanced diabetes and that this was associated with a survival
beneﬁt compared with patients on insulin, which is reserved
for patients who fail to achieve adequate diabetic control on
oral medication. However, only glyburide treatment and not
metformin was associated with an improvement in mortality.
We also considered whether thiazolidinediones and statins
(which are antiinﬂammatory and may be required more
commonly in diabetics) were confounders, but found that
although available, these medications are very rarely used in
our setting. This is an observational study in which glyburide
was given for a speciﬁc indication, namely, the treatment of
type 2 diabetes, and it is not possible to exclude unequivocally
the possibility of confounding [32]. We are currently seeking
to determine the effects of glyburide in directed clinical and
animal studies of bacterial sepsis.
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